Asia-Pacific Ovarian Cancer Diagnostics and therapeutics market - segmented by type of cancer and geography (2015-2020)

Description: The Asia-Pacific market for ovarian cancer diagnostics and therapeutics accounted for USD 165 million in 2015, and is anticipated to grow at a CAGR of 10-16% until 2020.

Ovarian cancer is caused by an uncontrollable cell growth in the ovarian tissue. It is a growing concern, as it is one of the most common causes of death in women across the globe. Thereby, the need to develop new medication and therapies for the effective treatment of this disease, and new methods for the timely diagnosis of ovarian cancer is increasing. Thus the market for ovarian cancer diagnostics and therapeutics is at a stage of huge development.

The market for ovarian cancer diagnostics and therapeutics is segmented on the basis of:

- Type
  - Epithelial ovarian tumors
  - Ovarian germ cell tumors
  - Ovarian stromal tumors
  - Primary peritoneal carcinoma
- Cancer stage
  - Stage I
  - Stage II
  - Stage III
  - Stage IV
- Diagnosis
  - Physical examination
  - Biopsy
  - Blood Tests
  - Human Chorionic Gonadotropin (hCG) test
  - Ultrasound
  - MRI
  - PET
  - CT scans
- Treatment
  - Chemotherapy
  - Localized ovarian cancer therapeutics
  - Metastatic ovarian cancer therapeutics
  - Recurrent ovarian cancer therapeutics
  - Targeted therapy
  - Radiation therapy
  - Immunotherapy
  - Hormonal therapy
  - Surgery

Geography

Asia-Pacific is expected to show high growth rates in the next few years in this market due to the large number of aging population and high prevalence of ovarian cancer. China and India are expected to be the fastest growing ovarian cancer markets in the Asia-Pacific region.

Some of the major companies operating in the ovarian cancer market are Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Astra Zeneca, Boehringer Ingelheim GmbH and F. Hoffman-La Roche Ltd.

Drivers

- Increasing incidences of ovarian cancer worldwide
- Increasing population of aged women
- Greater use of combination therapies for the treatment
- Increase in healthcare expenditure
- Increased government funding
- Increasing healthcare awareness

Restraints

- Launch of generic drugs
- Patent expiry of key drugs
- Lack of accurate diagnosis of ovarian cancer

Contents:

1. Introduction
  1.1 Report Description
  1.2 Research Methodology
2. Executive Summary
3. Market Overview
  3.1 Market Definition
  3.2 Market Drivers
    3.2.1 Increasing incidences of ovarian cancer
    3.2.2 Aging population of women
    3.2.3 Greater use of combination therapies for the treatment of Ovarian cancer
    3.2.4 Increase in healthcare expenditure
    3.2.5 Increased government funding
    3.2.6 Increasing healthcare awareness
  3.3 Market restraints
    3.3.1 The launch of generic drugs
    3.3.2 Patent expiry of key drugs
    3.3.3 Lack of accurate diagnosis of ovarian cancer
  3.4 Market Opportunities
  3.5 Market Threats
4. Porters Five Force Analysis
  4.1 Bargaining Power of suppliers
  4.2 Bargaining power of buyers
  4.3 Degree of competition
  4.4 Threat of substitution
  4.5 Threat of new entrants
5. Market Segmentation
  5.1 By Cancer Type
    5.1.1 Epithelial ovarian tumors
    5.1.2 Ovarian germ cell tumors
    5.1.3 Ovarian stromal tumors
    5.1.4 Primary Peritoneal Carcinoma
  5.2 By Cancer stage
    5.2.1 Stage I
      5.2.1.1 Stage IA
      5.2.1.2 Stage IB
      5.2.1.3 Stage IC
    5.2.2 Stage II
      5.2.2.1 Stage IIA
      5.2.2.2 Stage IIB
      5.2.2.3 Stage IIC
    5.2.3 Stage III
      5.2.3.1 Stage IIIA
      5.2.3.2 Stage IIIB
      5.2.3.3 Stage IIIC
    5.2.4 Stage IV

Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received.
5.3 Diagnosis
   5.3.1 Physical Examination
   5.3.2 Biopsy
   5.3.3 Blood Tests
   5.3.4 Human Chorionic Gonadotropin (hCG) Test
   5.3.5 Ultrasound
   5.3.6 MRI
   5.3.7 PET
   5.3.8 CT Scan
5.4 Treatment
   5.4.1 Chemotherapy
     5.4.1.1 Localized ovarian cancer therapeutics
     5.4.1.2 Metastatic ovarian cancer therapeutics
     5.4.1.3 Recurrent ovarian cancer therapeutics
   5.4.2 Targeted therapy
   5.4.3 Radiation Therapy
   5.4.4 Immunotherapy
   5.4.5 Hormonal therapy
   5.4.6 Surgery
5.5 By Geography
   5.5.1 Asia-Pacific
     5.5.1.1 India
     5.5.1.2 China
     5.5.1.3 Japan
     5.5.1.4 Singapore
     5.5.1.5 Rest of Asia Pacific
6. Competitive Landscape
7. Company Profiles
   7.1 Bristol Myers Squibb Company
   7.2 Eli Lilly and Company
   7.3 GlaxoSmithKline plc
   7.4 Janssen Pharmaceuticals, Inc.
   7.5 Novogen, Inc.
   7.6 Genentech Inc.
   7.7 Astra Zeneca
   7.8 Boehringer Ingelheim GmbH
   7.9 F. Hoffman-La Roche Ltd
8. Appendix
   8.1 Abbreviations
   8.3 Bibliography
   8.4 Disclaimer

Ordering:
   Order Online - http://www.researchandmarkets.com/reports/3784764/
   Order by Fax - using the form below
   Order by Post - print the order form below and send to
      Research and Markets,
      Guinness Centre,
      Taylors Lane,
      Dublin 8,
      Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Asia-Pacific Ovarian Cancer Diagnostics and therapeutics market - segmented by type of cancer and geography (2015-2020) |
| Web Address: | http://www.researchandmarkets.com/reports/3784764/ |
| Office Code: | SCBR3SDB |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 3850</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 7850</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

| Title: | Mr [ ]  Mrs [ ]  Dr [ ]  Miss [ ]  Ms [ ]  Prof [ ] |
|--------|-----------|---------|
| First Name: | | Last Name: |
| Email Address: * | | |
| Job Title: | | |
| Organisation: | | |
| Address: | | |
| City: | | |
| Postal / Zip Code: | | |
| Country: | | |
| Phone Number: | | |
| Fax Number: | | |

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number: 833 130 83
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World